Research library / Longevity compounds
AA Multiple randomized trials or meta-analyses, consistent results. How we grade →RCT · 6,522 Chinese patients with heart disease and impaired glucose tolerance
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
R Holman, R Coleman, J Chan, J Chiasson, H Feng, J Ge et al. The Lancet Diabetes & Endocrinology. 2017.
- In plain language
- ACE: acarbose did not lower cardiovascular events over a median 5 years (HR 0.98) but cut new diabetes by 18%.
- Limits
- Chinese patients with heart disease only. More stomach problems leading to stopping (7% vs 5%). Bayer among funders.
- Which of our grades it feeds
- DD Mostly mechanistic or early data. Shown openly. How we grade →Science summary: Notes on the Blueprint protocol
- Source
- doi.org/10.1016/S2213-8587(17)30309-1 · PubMed 28917545
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.